Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alphamab Oncology (HK:9966)
HKEX:9966
Holding HK:9966?
Track your performance easily
9966 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$2.00 - HK$6.98
Previous CloseHK$4.36
Volume3.70M
Average Volume (3M)5.34M
Market Cap
HK$4.21B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares OutstandingN/A
10 Day Avg. Volume8,118,600
30 Day Avg. Volume5,335,033
Standard Deviation0.24
R-Squared0.29
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alphamab Oncology News
PremiumCompany Announcements
Alphamab Oncology’s Promising Trial Results Bolster Prospects
PremiumCompany Announcements
Alphamab Oncology Granted Waiver for Key Appointment
PremiumCompany Announcements
Alphamab Oncology Grants Share Options to Employees
PremiumCompany Announcements
Alphamab Oncology Strengthens Leadership with New Appointments
PremiumCompany Announcements
Alphamab Oncology Unveils Board Structure and Strategy
PremiumCompany Announcements
Alphamab Oncology Partners with CSPC on Cancer DrugPremiumCompany Announcements
Alphamab Oncology’s Drug Shows Promise in Clinical StudiesPremiumCompany Announcements
Alphamab Oncology’s KN046 Trial Shows Promising ResultsOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.00% Mutual Funds
― Other Institutional Investors
96.86% Public Companies and
Individual Investors
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$2.00 and its highest was HK$6.98 in the past 12 months.
What is Alphamab Oncology’s market cap?
Currently, no data Available
When is Alphamab Oncology’s upcoming earnings report date?
Alphamab Oncology’s upcoming earnings report date is Mar 28, 2025 which is in 125 days.
How were Alphamab Oncology’s earnings last quarter?
Alphamab Oncology released its earnings results on Aug 16, 2024. The company reported -HK$0.054 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.054.
Is Alphamab Oncology overvalued?
According to Wall Street analysts Alphamab Oncology’s price is currently Overvalued.
Does Alphamab Oncology pay dividends?
Alphamab Oncology does not currently pay dividends.
What is Alphamab Oncology’s EPS estimate?
Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alphamab Oncology have?
Alphamab Oncology has 964,923,800 shares outstanding.
What happened to Alphamab Oncology’s price movement after its last earnings report?
Alphamab Oncology reported an EPS of -HK$0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.085%.
Which hedge fund is a major shareholder of Alphamab Oncology?
Currently, no hedge funds are holding shares in HK:9966
---
Alphamab Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.44%
12-Months-Change
Fundamentals
Return on Equity
-12.46%
Trailing 12-Months
Asset Growth
-8.37%
Trailing 12-Months
Company Description
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.
---
9966 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
InnoCare Pharma Ltd.
―
CanSino Biologics, Inc. Class H
―
Akeso, Inc.
―
Trip.com Group Ltd.
―
Best Analysts Covering 9966
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+60.70%
reiterated a buy rating 6 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +60.70% per trade.
---